Americas was the largest of Immucell Corp /De/’s 2 reported lines in fiscal 2025, at $24.39M — 88% of $27.64M.
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Americas | — | — | $22.89M | $24.39M | ||||
| United States | $17.02M | $15.95M | — | — | ||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | ||||
| Non-Us | — | — | $3.60M | $3.25M | ||||
| Other | $1.55M | $1.52M | — | — | ||||
| Other States | — | — | — | — | ||||
| Total | $18.57M | $17.47M | $26.49M | $27.64M |
In fiscal 2025, which ended December 31, 2025, the 2 regions Immucell Corp /De/ reported in this breakdown added up to $27.64M. That was up 4.3% from $26.49M in fiscal 2024. Americas was the largest region, at $24.39M or 88.2% of the total, followed by Non-Us ($3.25M, 11.8%).
Compared with fiscal 2024, Americas grew the fastest, rising 6.5% to $24.39M. Non-Us fell the most, down 9.6% to $3.25M.
Americas (fiscal 2024) and Non-Us (fiscal 2024) were first reported as separate regions during this period. The table also keeps 4 regions that Immucell Corp /De/ no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers 8 fiscal years between 2017 and 2025, as reported in Immucell Corp /De/'s annual filings.
Corporate Segment, Scours was the largest of Immucell Corp /De/’s 2 reported lines in fiscal 2025, at $27.45M — 99% of $27.64M.
| Statement Business Segments | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Corporate Segment, Scours | — | — | $26.31M | $27.45M | |
| Scours | $18.41M | $17.29M | — | — | |
| First Defense® | — | — | — | — | |
| Unallocated | — | — | — | — | |
| Corporate Segment, Mastitis | — | — | $178.92K | $196.39K | |
| Mastitis | $154.56K | $177.74K | — | — | |
| Other | $1.46K | — | — | — | |
| Total | $18.57M | $17.47M | $26.49M | $27.64M |
In fiscal 2025, which ended December 31, 2025, the 2 segments Immucell Corp /De/ reported in this breakdown added up to $27.64M. That was up 4.3% from $26.49M in fiscal 2024. Corporate Segment, Scours was the largest segment, at $27.45M or 99.3% of the total, followed by Corporate Segment, Mastitis ($196.39K, 0.7%).
Corporate Segment, Scours (fiscal 2024) and Corporate Segment, Mastitis (fiscal 2024) were first reported as separate segments during this period. The table also keeps 5 segments that Immucell Corp /De/ no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 5 fiscal years between 2020 and 2025, as reported in Immucell Corp /De/'s annual filings.
First Defense® Product Line was the largest of Immucell Corp /De/’s 2 reported lines in fiscal 2024, at $26.31M — 99% of $26.49M.
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| First Defense® Product Line | $18.93M | $18.41M | $17.29M | $26.31M | ||||
| First Defense Product Line | — | — | — | — | ||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | ||||
| Other Animal Health | $309.88K | $156.01K | $177.74K | $178.92K | ||||
| Other Product Services | — | — | — | — | ||||
| Total | $19.24M | $18.57M | $17.47M | $26.49M |
In fiscal 2024, which ended December 31, 2024, the 2 revenue lines Immucell Corp /De/ reported in this breakdown added up to $26.49M. That was up 51.6% from $17.47M in fiscal 2023. First Defense® Product Line was the largest revenue line, at $26.31M or 99.3% of the total, followed by Other Animal Health ($178.92K, 0.7%).
Over fiscal 2021 to 2024, revenue across these revenue lines went from $19.24M to $26.49M, a compound annual growth rate of 11.2%. First Defense® Product Line's share of the total rose from 98.4% to 99.3% over the same years.
The table also keeps 3 revenue lines that Immucell Corp /De/ no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2024, as reported in Immucell Corp /De/'s annual filings.
Immucell Corp /De/ (ICCC) breaks its revenue down by region, segment and revenue line. In fiscal 2025, its largest region was Americas, with $24.39M or 88.2% of the total, followed by Non-Us at $3.25M (11.8%).
Americas was Immucell Corp /De/'s largest region in fiscal 2025, with $24.39M in revenue, 88.2% of the $27.64M reported across its 2 regions.
Corporate Segment, Scours was Immucell Corp /De/'s largest segment in fiscal 2025, with $27.45M in revenue, 99.3% of the $27.64M reported across its 2 segments.
First Defense® Product Line was Immucell Corp /De/'s largest revenue line in fiscal 2024, with $26.31M in revenue, 99.3% of the $26.49M reported across its 2 revenue lines.
Of the Immucell Corp /De/ regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Americas grew the fastest, rising 6.5% from $22.89M to $24.39M.
Every figure is taken from Immucell Corp /De/'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2017 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.